News

Categories
Sign up
Featured Posts
Archive
Follow Us
  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon

New Radiotherapy Approach Deemed Safe for Clinical Trials

The Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), has approved Alpha Tau Medical’s Alpha DaRT cancer treatment as a Sealed Source and Device (SSD). https://www.dotmed.com/news/story/44162 Granting of the certification deems the radiotherapy solution a suitable candidate for clinical trials at U.S. cancer centers in the treatment of various types of solid tumors. Known as Diffusing Alpha-emitters Radiation Therapy, the approach is the first alpha radiation-based cancer treatment for various types of solid tumors. “The Alpha DaRT applicators are designed to ensure that the Alpha DaRT Seeds and the radioactive isotopes will be r

Israeli Oncology Company Alpha Tau is Raising Funds

Alpha Tau is in the last stages of raising an investment of several tens of millions of dollars. Israeli oncology company Alpha Tau Medical Ltd. is in the last stages of raising an investment of several tens of millions of dollars, one person familiar with the matter told Calcalist on condition of anonymity. The round is expected to close by the end of the month, that person said. Alpha Tau raised $25 million to date. Cancer tumor (illustration). Photo: medscape Founded in 2016 and headquartered in Tel Aviv, clinical-stage Alpha Tau uses alpha radiation to treat various types of solid tumors. The technique, called Alpha DaRT (Dіffusіng Alpha-emіtters Radіatіon Therapy), was developed by two

Alpha Tau’s High-Precision Cancer Radiotherapy Receives Radioactive-Safety Approval in the United St

The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). Boston, MA, August 21st 2018 -- Israel MedTech startup, Alpha Tau Medical, is proud to announce that the Massachusetts Radiation Control Program (RCP), under agreement with the U.S. Nuclear Regulatory Commission (NRC), approved the company’s treatment, the Alpha DaRT, as a Sealed Source and Device (SSD). The new approval enables the initiation of clinical trials in leading cancer centers across the U.S which are interested in investigating the Alpha DaRT as a

Israeli Medical Startups Beat a Path to Aging Japan

[..] Another company from Tel Aviv, Alpha Tau Medical, has partnered with Japanese biotechnology startup HekaBio to release radiation therapy equipment in Japan in 2021, at the earliest. The product is designed to treat patients with breast, skin and other solid cancers. Unlike most such equipment, Alpha Tau's "radioactive seeds" emit alpha rays from inside the body. These rays are more powerful than other forms of radiation but are less likely to damage surrounding cells. HekaBio CEO Robert Claar has high hopes the device will prove practical. "We can provide this therapy at lower prices than external radiation therapies," he said. [...]

Alpha Tau

Looking for clinical trials?

  • Grey Facebook Icon
  • Grey LinkedIn Icon
  • Grey Twitter Icon